Company intelligence / Profile preview
Lee's Pharmaceutical Holdings Limited
Sha Tin, Hong Konglee-pharm.com ↗
- Ownership
- Public · 0950
- Development stage
- Other
01
Overview
Lee's Pharmaceutical has a robust pipeline with over 40 projects in various stages of development. The company has 18 products available in China, Hong Kong, Macau, and Taiwan. Recent approvals include Azilsartan tablets and Apremilast tablets in China.[5][4]
- Therapeutic areas
- CardiovascularOphthalmologyDermatologyOtherWomen's HealthOncologyRare DiseasesInfectious Diseases
- Modalities
- Small molecule drugsBiological productsSynthetic peptidesInterferons
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
03
Partnerships
Windtree TherapeuticsSorrento Therapeutics
04
Financials
- Market cap
- $79.6M
- Total revenue
- $183.2M
- Enterprise value
- $65M
Beyond the preview
Go deeper on Lee's Pharmaceutical Holdings Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lee's Pharmaceutical Holdings Limited.